导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -7.46% | 3599/4773 |
| 近一周 | -3.45% | 4196/5462 |
| 近一月 | -9.86% | 4893/5421 |
| 近一季 | -5.64% | 1887/5209 |
| 近半年 | -12.15% | 3766/4920 |
| 近一年 | -11.68% | 3520/4366 |
| 近两年 | 64.74% | 1080/2954 |
| 近三年 | 11.42% | 1708/2253 |
| 成立以来 | 38.46% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.27% 3584/4961 |
12.12% 2225/5312 |
- - |
- - |
| 2025 | 13.96% 2622/4813 |
4.91% 864/3635 |
-2.17% 3320/4076 |
23.77% 1515/4524 |
-10.28% 4149/4813 |
| 2024 | 11.27% 1335/3463 |
-6.46% 2055/2808 |
-12.20% 2592/3014 |
19.64% 820/3129 |
13.24% 156/3463 |
| 2023 | -1.79% 534/2656 |
35.86% 54/2280 |
-8.90% 2020/2385 |
-15.60% 2230/2515 |
-5.99% 1581/2655 |
| 2022 | -26.02% 1364/2207 |
-21.98% 1677/1919 |
-2.26% 1770/2016 |
-14.67% 1132/2113 |
13.69% 94/2208 |
| 2021 | 0.48% 711/1822 |
-6.23% 988/1255 |
12.42% 332/1330 |
-7.80% 1083/1466 |
3.38% 445/1822 |
| 2020 | 23.55% 652/1250 |
3.91% 102/1028 |
18.24% 349/1067 |
0.87% 1036/1164 |
-0.30% 1070/1184 |
| 2019 | - - |
- - |
- - |
- - |
5.46% 716/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰中证计算机ETF VS. 长安沪深300非周期A(740101) |